TABLE 2.
MICs of B. pseudomallei clinical isolates with elevated cefiderocol concentrations
| Isolate IDa |
B. pseudomallei isolate metadata collection |
Clinically relevant antimicrobial (mg/liter) and categoryb
|
||||||
|---|---|---|---|---|---|---|---|---|
| Site | Yr | FDC | MEM | CAZ | AMC | SXT | DOX | |
| C137Rc | SSTI | 2016 | 16 | 1 | 2 | >32 R | 0.5/9.5 | 2 |
| C4 | Lung | 2006 | 8 | >16 R | 2 | >32 R | 0.12/2.28 | 2 |
| C50 | Lung | 2000 | 4 | 4 | ≥16 NS | >32 R | 4/76 R | 4 |
| C194 | Blood | 2018 | 16 | >16 R | 2 | >32 R | 0.12/2.28 | 2 |
a
ID, identifier.
b
FDC, cefiderocol. Clinically relevant antimicrobials included meropenem (MEM), ceftazidime (CAZ), amoxicillin-clavulanic acid (AMC), trimethoprim-sulfamethoxazole (SXT), and doxycycline (DOX). Nonsusceptible (NS) and resistant (R) categories were determined by CLSI breakpoints.
c
Broth microdilution testing was performed on isolate C137 as the resistant subpopulation was not able to be subcultured from this sample.